Wikipedia

User:Mr. Ibrahem/Afamelanotide

< User:Mr. Ibrahem
Mr. Ibrahem/Afamelanotide
Clinical data
Pronunciation/ˌæfəmɛˈlænoʊtaɪd/ ⓘ
Trade namesScenesse
Other names[Nle4,D-Phe7]α-MSH; NDP-α-MSH; NDP-MSH; Melanotan; Melanotan-1; Melanotan I; EPT1647; CUV1647;
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: B1
Routes of
administration		Subcutaneous implant
Drug classMC1-R activator[1]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Pharmacokinetic data
Elimination half-life30 minutes[2]
Identifiers
  • N-acetyl-L-seryl-L-tyrosyl-L-seryl-L-norleucyl-L-α-glutamyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophylglycyl-L-lysyl-L-prolyl-L-valinamide
Chemical and physical data
FormulaC78H111N21O19
Molar mass1646.874 g·mol−1
3D model (JSmol)
  • CCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NCC(=O)NC(CCCCN)C(=O)N5CCCC5C(=O)NC(C(C)C)C(=O)N)NC(=O)C(CO)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(CO)NC(=O)C
  • InChI=1S/C78H111N21O19/c1-5-6-19-52(91-75(116)61(41-101)97-72(113)57(34-46-24-26-49(103)27-25-46)94-74(115)60(40-100)88-44(4)102)68(109)92-54(28-29-64(105)106)70(111)96-59(36-48-38-83-42-87-48)73(114)93-56(33-45-16-8-7-9-17-45)71(112)90-53(22-14-31-84-78(81)82)69(110)95-58(35-47-37-85-51-20-11-10-18-50(47)51)67(108)86-39-63(104)89-55(21-12-13-30-79)77(118)99-32-15-23-62(99)76(117)98-65(43(2)3)66(80)107/h7-11,16-18,20,24-27,37-38,42-43,52-62,65,85,100-101,103H,5-6,12-15,19,21-23,28-36,39-41,79H2,1-4H3,(H2,80,107)(H,83,87)(H,86,108)(H,88,102)(H,89,104)(H,90,112)(H,91,116)(H,92,109)(H,93,114)(H,94,115)(H,95,110)(H,96,111)(H,97,113)(H,98,117)(H,105,106)(H4,81,82,84)/t52-,53-,54-,55-,56+,57-,58-,59-,60-,61-,62-,65-/m0/s1 checkY
  • Key:UAHFGYDRQSXQEB-LEBBXHLNSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent skin damage from the sun in erythropoietic protoporphyria.[1] It increases the amount of light exposure before pain occurs.[1] It is used as an implant under the skin.[1]

Common side effects include nausea, cough, tiredness, sleepiness, increased skin pigmentation, and skin irritation.[1] It should not be used in people with kidney or liver problems.[4] Safety in pregnancy is unclear.[1] It is a melanocortin 1 receptor (MC1-R) activator, which increases the amount of dark pigment produced by the skin.[1][4]

Afamelanotide was approved for medical use in Europe in 2015 and the United States in 2019.[5][4] As of 2022 it is not currently available in the United Kingdom.[6] In the United States it costs 49,000 USD per implant as of 2022.[7]

References edit

  1. ^ a b c d e f g h i "DailyMed - SCENESSE- afamelanotide implant". dailymed.nlm.nih.gov. Archived from the original on 13 January 2022. Retrieved 13 January 2022.
  2. ^ "Scenesse: Summary of Product Characteristics" (PDF). European Medicines Agency (EMA). 27 January 2016. Archived (PDF) from the original on 6 April 2017. Retrieved 6 April 2017. For updates see EMA Index page Archived 29 August 2018 at the Wayback Machine
  3. ^ "Afamelanotide (Scenesse) Use During Pregnancy". Drugs.com. 3 January 2020. Archived from the original on 2 January 2020. Retrieved 26 January 2020.
  4. ^ a b c "Scenesse". Archived from the original on 19 November 2019. Retrieved 13 January 2022.
  5. ^ "Afamelanotide (Topical) Monograph for Professionals". Drugs.com. Archived from the original on 27 January 2021. Retrieved 13 January 2022.
  6. ^ "Afamelanotide". SPS - Specialist Pharmacy Service. 28 January 2016. Archived from the original on 14 September 2019. Retrieved 13 January 2022.
  7. ^ "Scenesse Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 3 March 2021. Retrieved 13 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Afamelanotide&oldid=1213862086"